Clinical Trials
Sponsor:
Sponsor Study ID:
Study Title:
A Phase 1/2 Study of NM21 1480 (Anti PDL 1/Anti 4 1BB/Anti HSA Tri Specific Antibody) in Adult Patients With Advanced Solid Tumors
NCT Number:
NCT04442126
Phase:
I/II
Protocol Type:
Treatment
Age Group:
Adults
Disease Sites:
Lip, Oral Cavity and Pharynx, Anus, Lung, Ovary, Other Female Genital, Other Male Genital, Cervix Uteri
Study Objectives:
This is a first-in-human, open-label, multi-center, Phase 1/2, dose-escalation study with expansion cohorts to evaluate NM21-1480 for safety and immunogenicity, to determine the maximal tolerated dose and recommended Phase 2 dose, define the pharmacokinetics, to explore the pharmacodynamics, and to obtain preliminary evidence of the clinical activity in adult patients with selected advanced solid tumors.
Study Documents
(MUSC NetID required for document access)